2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.16 (Poster) Evaluation of Lines of Therapy Amongst Patients with NSCLC Tested with a Host Immune Classifier (HIC) in a Real-World Setting

PP01.16 (Poster) Evaluation of Lines of Therapy Amongst Patients with NSCLC Tested with a Host Immune Classifier (HIC) in a Real-World Setting

Back to course

Pdf Summary

A study presented at the IASLC 2023 North America Conference on Lung Cancer examined the evaluation of lines of therapy among patients with non-small cell lung cancer (NSCLC) tested with a Host Immune Classifier (HIC) in a real-world setting. The HIC is a blood-based immune profiling test that provides personalized information on each patient's immune response to their lung cancer.<br /><br />The study aimed to describe healthcare resource utilization and costs among patients with lung cancer after using the HIC, as well as treatment patterns by line of therapy. The researchers analyzed data from a total of 328 patients who met the inclusion/exclusion criteria. Of these, 180 patients were analyzable for the first line of therapy (LOT) for lung cancer.<br /><br />The results showed that patients with HIC-H categorization, indicating a more aggressive disease, were more likely to receive biologic or targeted therapy compared to patients with HIC-C categorization. HIC-H patients had a slightly longer duration of the first LOT compared to HIC-C patients. The majority of HIC-C patients moved on to subsequent lines of therapy, while fewer HIC-H patients did.<br /><br />The study concluded that HIC testing could help route patients to appropriate therapies and guide treatment decision-making. Providers may be utilizing the test for treatment decisions, as patients with HIC-H status were more likely to be routed to biologic or targeted therapy. Additionally, earlier identification of HIC-C and HIC-H patients could help determine the need for additional therapies or multi-drug regimens.<br /><br />Overall, the study highlights the potential benefits of using the HIC test in real-world clinical practice, contributing to more personalized and effective treatment strategies for patients with NSCLC.

Asset Subtitle

Kimberly Le

Keywords

IASLC 2023 North America Conference on Lung Cancer

non-small cell lung cancer

Host Immune Classifier

HIC

blood-based immune profiling test

healthcare resource utilization

treatment patterns

biologic therapy

targeted therapy

first line of therapy